Severe and fatal adverse events of immune checkpoint inhibitor combination therapy in patients with metastatic renal cell carcinoma: a systematic review and meta-analysis
IntroductionImmune checkpoint inhibitor (ICI) combination therapy has changed the treatment landscape for metastatic renal cell carcinoma (mRCC). However, little evidence exists on the treatment-related severe adverse events (SAEs) and fatal adverse events (FAEs) of ICI combination therapy in mRCC.M...
Những tác giả chính: | , , , , , , |
---|---|
Định dạng: | Bài viết |
Ngôn ngữ: | English |
Được phát hành: |
Frontiers Media S.A.
2023-06-01
|
Loạt: | Frontiers in Immunology |
Những chủ đề: | |
Truy cập trực tuyến: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1196793/full |